Enterprise Value
14.6M
Cash
137.8M
Avg Qtr Burn
-15.54M
Short % of Float
6.50%
Insider Ownership
5.61%
Institutional Own.
86.70%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
RLYB212 Details Fetal and Neonatal Alloimmune Thrombocytopenia | Phase 1b Data readout | |
RLYB116 Details Fetal and Neonatal Alloimmune Thrombocytopenia | Phase 1 Data readout | |
RLYB211 Details Fetal and Neonatal Alloimmune Thrombocytopenia | Failed Discontinued |